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HSE cases (n = 3) compared to controls (n = 5). Brain 
tissue exhibited a significant inverse correlation for immu-
nostaining between cytochrome c oxidase subunit 1 (CO1), 
a MtDNA encoded enzyme subunit, and HSV-1; with lower 
abundance for mitochondrial protein in regions where 
HSV-1 was abundant. Preferential loss of mitochondrial 
function, among MtDNA encoded components, was con-
firmed using an in vitro primary human astrocyte HSV-1 
infection model. Dysfunction of cytochrome c oxidase 
(CO), a mitochondrial enzyme composed predominantly 
of MtDNA encoded subunits, preceded that of succinate 
dehydrogenase (composed entirely of nuclear encoded 
subunits). Minocycline treated astrocytes exhibited higher 
CO1 transcript abundance, sustained CO activity and cell 
viability compared to non-treated astrocytes. Based on 
observations from HSE patient tissue, this study highlights 
mitochondrial damage as a critical and early event during 
HSV-1 infection. We demonstrate minocycline preserves 
Abstract Herpes simplex virus type-1 (HSV-1) encephali-
tis (HSE) is the most commonly diagnosed cause of viral 
encephalitis in western countries. Despite antiviral treat-
ment, HSE remains a devastating disease with high morbid-
ity and mortality. Improved understanding of pathogenesis 
may lead to more effective therapies. Mitochondrial dam-
age has been reported during HSV infection in vitro. How-
ever, whether it occurs in the human brain and whether this 
contributes to the pathogenesis has not been fully explored. 
Minocycline, an antibiotic, has been reported to protect 
mitochondria and limit brain damage. Minocycline has not 
been studied in HSV infection. In the first genome-wide 
transcriptomic study of post-mortem human HSE brain 
tissue, we demonstrated a highly preferential reduction in 
mitochondrial genome (MtDNA) encoded transcripts in 
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mitochondrial function and cell viability during HSV-1 
infection. Minocycline, and mitochondrial protection, 
offers a novel adjunctive therapeutic approach for limit-
ing brain cell damage and potentially improving outcome 
among HSE patients.
Keywords Human · Herpes simplex virus encephalitis · 
Mitochondria · Minocycline · Gene-expression
Introduction
Herpes simplex virus (HSV) is one of the most common 
causes of viral encephalitis in western countries. HSV-1 
type 1 (HSV-1) is the predominant cause of herpes simplex 
encephalitis (HSE). Despite treatment with aciclovir, HSE 
is associated with 20 % mortality, and two-thirds of sur-
vivors never regain normal central nervous system (CNS) 
function. Improved understanding of the pathogenesis of 
HSE and more effective treatments are required [47, 52].
Multiple studies have described the brain pathology in 
human HSE cases and animal models of HSV-1 infection. 
Less is known about the molecular mechanisms underlying 
this damage. Studies examining the pathogenesis of HSE 
have tended to use animal in vivo and in vitro models or 
transformed human cell lines derived from cells outside 
the brain [13, 20, 45]. Phylogenetically and/or functionally 
distinct from the human brain, such models may not accu-
rately reflect human HSE.
Damage to mitochondria could significantly contribute 
to the pathogenesis of HSE. Mitochondria are essential for 
energy production and cell survival [15]. They contain their 
own genome, the mitochondrial DNA (MtDNA). MtDNA 
encodes for proteins, such as cytochrome c oxidase subu-
nit 1 (CO1), which compose key mitochondrial enzymes, 
including cytochrome c oxidase (CO), involved in energy 
production [15, 37]. In vitro studies, largely using non-
neuronal or transformed cell lines, have shown that HSV-1 
interacts with mitochondria, including migration of viral 
proteins into the mitochondria, and can cause depletion of 
mitochondrial DNA, RNA and proteins, and impair mito-
chondrial activity [13, 33, 40, 45]. However, whether mito-
chondrial damage occurs in the human brain, and whether 
this drives brain cell death has not been fully explored.
Minocycline, an antibiotic, has been reported to reduce 
damage in CNS models of ischaemic stroke, neuro-degen-
eration, traumatic brain injury and viral infection [38, 39, 
42, 53–55]. Two small clinical trials have previously indi-
cated minocycline improves patient outcome in acute 
stroke. However, more recent trials did not show any effi-
cacy [29, 32, 41]. Trials are ongoing in Japanese encepha-
litis and neurodegenerative diseases [19, 28]. Minocycline 
has not always shown benefit, and there are reports of 
minocycline exacerbating brain damage in animal models, 
including for hypoxic brain injury, Parkinson’s disease and 
Huntington’s disease [53]. Nevertheless, the findings sug-
gest minocycline may be worth investigating as an adjunct 
in HSE. Minocycline is reported to limit damage through a 
variety of mechanisms, including mitochondrial protection, 
anti-inflammatory, anti-apoptotic and anti-viral properties 
[27, 53].
To identify key host responses perturbed during HSE, 
we examined genome-wide transcript abundance in post-
mortem brain tissue from human HSE cases and controls. 
Observing a marked loss of mitochondrial transcripts 
among HSE cases, we examined whether the reduction 
of the mitochondrial protein (CO1) was topographically 
linked to the presence of HSV-1 proteins in the HSE brain 
tissue. To determine whether HSV triggered mitochondrial 
damage we examined HSV-1 DNA abundance, mitochon-
drial enzyme activity and cell viability during the infec-
tion time-course using primary human astrocytes. Primary 
human astrocytes were used because they are infected dur-
ing human HSE, their dysfunction contributes to neuronal 
death, and they can be more reliably grown in vitro com-
pared to primary human neurons [21, 46]. To test whether 
MtDNA encoded enzyme activity is impaired before 
nuclear DNA encoded enzyme activity, we compared CO 
and succinate dehydrogenase function (the latter encoded 
entirely nuclear DNA encoded). Next, we used transmis-
sion electron microscopy to identify whether mitochon-
drial disruption preceded nuclear disruption. Directed by 
the observed mitochondrial damage, we examined whether 
minocycline could protect mitochondria during HSV-1 
infection.
Materials and methods
Post-mortem brain tissue was obtained from Thomas Willis 
Brain Bank, Oxford University. The Thomas Willis Brain 
Bank review board gave ethical approval for this study.
For histopathological analysis, pre-mounted, 10 µm 
thick serial sections of formalin-fixed paraffin-embedded 
tissue from six brain regions (frontal, amygdala, thalamus, 
hippocampus, cingulate gyrus and insular cortex) of adult 
HSE cases (n = 3) and control subjects (n = 5) with a 
cause of death not related to encephalitis (i.e. pneumonia or 
myocardial infarction) were stained with haematoxylin and 
eosin (H&E). Patient clinical information is summarised in 
Supplementary table S1 (Online Resource 1).
Immunoperoxidase (IP) staining for HSV-1 and CO1 
was performed on consecutive sections derived from the 
same anatomic region and capturing the same field of view. 
IP staining against a single target antigen provided the most 
consistent results across the tissue regions. After enzymatic 
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antigen retrieval with citrate buffer (pH 6.0), slides were 
incubated with primary rabbit anti-HSV-1 polyclonal anti-
body [1:800 dilution in Tris buffered saline with 0.05 % 
Tween 20 (TBST); Abcam] and primary mouse anti-CO1 
monoclonal antibody (clone 1D6E1A8; 1:200 dilution 
in TBST; Abcam). Dako EnVision plus® detection sys-
tem, containing secondary goat anti-rabbit and anti-mouse 
antibodies and 3′3′9-diaminobenzidine tetrahydrochlo-
ride (DAB) as chromogen, was employed for visualisa-
tion (dilutions were made following the manufacturer’s 
instructions).
Dual immunofluorescent (IF) staining against HSV-1 
and translocase of the outer mitochondrial membrane 70a 
(TOMM70) with DAPI as nuclear counter-stain, plus dou-
ble IP staining for CO1 and HSV-1 were also performed on 
the tissue. Methods are documented in Online resource 2.
For the microarray studies, total RNA was extracted 
from 5 mm2 blocks of FFPE tissue. Tissue was de-paraffin-
ised with d-limolene, rehydrated with ethanol, incubated 
with proteinase K for 18 h at 55 °C, and homogenised. 
Total RNA was extracted using Trizol (Life-Technologies) 
and treated with TURBO-DNase (Applied Biosystems) 
following the manufacturers’ instructions. Total RNA 
(500 ng per subject) was amplified using genome-wide 
Transplex Whole Transcriptome Amplification Kit (Sigma-
Aldrich). Amplified RNA was labelled with Cyanine-3 via 
the non-enzymatic Universal Linkage System (Kreatech). 
Labelled RNA (200 ng) was hybridised to SurePrint G3 GE 
8 × 60 K (Design ID 030495) human-specific microarrays, 
and scanned using G2505C scanner following the manu-
facturers’ instructions (Agilent Technologies). The array 
was custom designed to include 398 transcripts (includes 
replicates) encoding for 33 MtDNA encoded genes. Raw 
fluorescent intensity was measured and initial quality con-
trol assessment undertaken using Agilent Feature Extrac-
tion software (FE 10.5.1.1). Transcripts were analysed as 
previously described [24]. Briefly, background subtracted 
fluorescent intensity for each gene-probe was median cen-
tred, with transcripts (n = 2882) exhibiting >0.8 standard 
deviations in variation of abundance across the samples 
selected using Cluster 3.0, and visualised as a heat-map 
using Treeview 1.60 (http://www.eisenlab.org). Significant 
changes in transcript abundances [<5 % false detection rate 
(FDR)] were identified using SAM 4.0 (http://www-stat.
stanford.edu/~tibs/SAM). Gene ontology over-represen-
tation analysis was undertaken among significantly and 
differentially expressed transcripts using the over-repre-
sentation analysis program within InnateDB (http://www.
innatedb.com) [6]. Significant over-representation was cal-
culated via a hypergeometric algorithm using Benjamini 
Hochberg correction [25]. Gene-expression data is avail-
able at GEO (http://www.tobeconfirmed).
In vitro cell culture: Primary human astrocytes (Scien-
Cell Research Laboratories) were cultured in Dulbecco’s 
modified Eagle’s medium-F12 (Sigma-Aldrich) with 10 % 
fetal bovine serum, 1 % l-glutamine and 1 % penicillin/
streptomycin solution (Sigma-Aldrich). In all experiments 
astrocytes were at confluence and between passages 4 and 
5. HSV-1 strain SC16 (propagated in Vero cells) was inocu-
lated at a multiplicity of infection (MOI) of 0.01. Viral rep-
lication and mitochondrial activity were monitored 6–72 h 
post infection (pi). When testing pharmacological agents, 
minocycline (Sigma-Aldrich) was added at a final concen-
tration of 60 µM, 1 h prior to HSV-1 inoculation and 24, 48 
and 72 h pi. Examining minocycline in combination with 
aciclovir (Sigma-Aldrich), both drugs were added at a final 
concentration of 20 µM at the same time-points. In the lat-
ter experiments, a lower concentration of minocycline was 
used in combination with aciclovir, this concentration was 
more in-line with final concentrations achievable in the 
cerebrospinal fluid in humans [1, 22]. A minimum of three 
experimental replicates were performed.
Quantitative PCR (qPCR) in cell cultures: total RNA was 
extracted using Qiaquick RNAeasy kit (Qiagen). cDNA 
was synthesised from 1 µg of total RNA using RetroScript 
kit (Ambion). Viral DNA was extracted using Qiaquick 
viral kit (Qiagen). qPCR was performed with 50 ng of 
cDNA or 1 µl of viral DNA using TaqMan Gene-Expres-
sion Assays (Applied Biosystems) in a BioRad qPCR sys-
tem following the manufacturer’s assay and thermo-cycler 
set-up instructions. Relative target transcript abundance for 
mitochondrial cytochrome oxidase 1 (CO1), tumour necro-
sis factor (TNF), interleukin 6 (IL-6), Caspase 3 (CASP3), 
B cell lymphoma 2 (BCL-2), BCL-2 associated X protein 
(BAX) was quantified using the δCT method [50]. Change 
in HSV-1 abundance over time was expressed as the PCR 
fractional cycle number at which threshold fluorescence 
was achieved (CT). Differences in relative transcript abun-
dance (CT, δCT or δδCT) in the target gene was compared 
between exposed and non-exposed (i.e. HSV-1 infection or 
minocycline) across multiple time-points using a two-way 
repeated measures analysis of variance (ANOVA). Time-
point was the row factor (repeated measure) and exposure 
of the column factor. When a single time-point was com-
pared, the Mann–Whitney U test was employed. DAD1 
(defender against cell death 1), which exhibited relatively 
invariable abundance between HSE cases and controls in 
the array data, which was used as the ‘house-keeping’ gene.
qPCR in brain tissue
cDNA was synthesised from 500 ng of total RNA. Changes 
in CO1 were expressed as 1/CT. Difference in 1/CT for 
CO1 was compared across three brain regions (cingulate, 
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amygdala and frontal), two brain sections per region, 
among cases and controls using a two-way repeated meas-
ures ANOVA. Tissue section was the row factor (repeated 
measure), and case or control the column factor. Statistical 
analysis and plot generation were performed using Graph-
Pad Prism 6.0 (GraphPad software). Primer sequences are 
provided in Online Resource 1.
Enzyme activity for two mitochondrial enzymes, CO 
and succinate dehydrogenase (SDH), was sequentially 
examined in monolayers of non-fixed astrocytes as previ-
ously described [11]. In cells with intact CO function, DAB 
is oxidised to a brown end-product that saturates the orga-
nelles. Cell saturation with DAB prevents accumulation of 
the product of SDH activity [reduced Nitro Blue Tetrazo-
lium (NBT)]. In cells with impaired CO function, but intact 
SDH function, NBT is reduced to a blue end-product that 
accumulates inside the cell. The proportion of astrocytes 
exhibiting CO function was quantitatively assessed using 
ImageJ (http://imagej.nih.gov/ij/). Images of the astrocyte 
monolayer were captured at 20× magnification using a 
CETI Inverso T100 inverted microscope (Medline Scien-
tific). Measurements were initially set to measure the over-
all picture area (analyse: set measurements: select area and 
integrated density; then analyse: measure). The ImageJ 
thresholding tool was then used to manually adjust image 
brightness, saturation and hue (image: adjust: threshold) 
to select cells positively stained for DAB. The proportion 
(%) of the cells stained for DAB was calculated with the 
overall picture area as 100 %. At least three fields of view 
per experimental group at each time-point from three inde-
pendent experiments were examined. To mitigate analysis 
bias, masked images were also examined by two additional 
independent technicians. They ranked the images by area 
of monolayer positively stained for DAB.
Dual IF labelling for HSV-1 and CO1 was performed 
on astrocyte pellet monolayers fixed with 4 % paraformal-
dehyde. A primary rabbit anti-HSV-1 polyclonal antibody 
(1:400 dilution in TBST; Abcam) and primary mouse anti-
CO1 monoclonal antibody (clone 1D6E1A8; 1:100 dilution 
in TBST; Abcam) were employed. Secondary anti-rabbit 
polyclonal antibody conjugated with DyLight549 (1:200 
dilution in TBST; MenaPath) and secondary anti-mouse 
polyclonal antibody conjugated with DyLight488 (1:200 
dilution in TBST; AbDSerotec) were used to obtain red 
and green fluorescence, respectively. Nuclei were counter-
stained with blue fluorescent DAPI nucleic acid stain (Life-
Technologies). Images (four fields of view per pellet) were 
examined using an Eclipse 80i epi-fluorescent microscope 
(Nikon). The examiner was blinded to infection exposure 
and experimental time-point. Among DAPI positive cells, 
the number of cells stained for CO1 and/or HSV-1 was 
counted.
For transmission electron microscopy, pellets of astro-
cytes (recovered from the infection time-course) were 
fixed with 2.5 % glutaraldehyde (in 0.2 M sodium caco-
dylate buffer) and 1 % aq osmium tetroxide, stained with 
2 % uranyl acetate and dehydrated. Cells were embedded 
in epoxy resin (TAAB) and polymerised at 60 °C over-
night. 75 nm sections contrasted with lead citrate and ura-
nyl acetate were examined using a Philips EM208S (FEI) 
at 80 kV with an ES500 W Gatan charge-coupled cam-
era (Erlangshen). Twenty (5 per group: non-infected and 
24, 48, 72 h pi) ultra-photographs (taken at 8000× mag-
nification) were examined. The examiner was blinded to 
which group the images belonged. The number of nor-
mally conformed mitochondria inside the cells was quan-
tified. Normally conformed mitochondria were defined as 
electron-dense elongated organelles with identifiable dou-
ble membrane and multiple cristae without ultra-structural 
pathological features.
Dual glial fibrillary acidic protein (GFAP) and HSV-1 
IF labelling, as well as Trypan Blue staining were also per-
formed on cultured astrocytes (Methods; Online resource 
3).
Results
H&E stained HSE tissue sections [6 brain regions per 
patient (n = 3)] demonstrated a necrotizing and non-sup-
purative polioencephalitis with micro-haemorrhages and 
occasional parenchymal rarefaction with gitter cell infil-
tration and gliosis. Pyknotic and karyolytic hyperoeosino-
philic neurons (Fig. 1a) were frequently observed in asso-
ciation with numerous astrocytes containing intranuclear 
eosinophilic (Cowdry type A) inclusion bodies (Fig. 1b, c). 
Extensive inflammatory infiltrates and haemorrhages, that 
effaced and replaced grey matter, were more frequently 
seen in frontal and temporal cortices (Fig. 1d). No sig-
nificant neuropathological changes were observed in the 
control tissue (Fig. 1e). HSV-1 antigen staining of hip-
pocampal HSE tissue confirmed, the astrocyte intranuclear 
inclusions were composed of viral particles (Fig. 1f). Fur-
ther details of the pathological features observed among the 
HSE patients and brain regions are summarised in Table S2 
(Online resource 1).
To aid comparison with control tissue, and to avoid using 
HSE tissue exhibiting frank necrosis, the gene-expression 
microarray experiments were undertaken using RNA recov-
ered from the cingulate region. 287 transcripts exhibited 
significantly (FDR <5 %) lower abundance in HSE com-
pared to control tissue (Fig. 2). MtDNA encoded transcripts 
represented only 398/62977 (0.6 %) of the total number of 
transcripts on the array (the array contained multiple probes 
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for each mitochondrial gene). These mitochondrial tran-
scripts were highly significantly over-represented, account-
ing for 219 out of 287 (76 %) transcripts in the signifi-
cantly lower abundant set of transcripts (p < 0.0001). These 
transcripts encoded for 28 out of 33 MtDNA genes on the 
array (Tables S3 and S4; Online Resource 1). Examining 
all mitochondrial related transcripts (nuclear and mito-
chondrial genome encoded), there was a greater decline in 
abundance for MtDNA encoded compared to nuclear DNA 
encoded transcripts in HSE cases compared to controls. For 
example, focusing on cytochrome c oxidase, a mitochon-
drial enzyme composed of three mitochondrial encoded 
Fig. 1  Histological features of HSE: a HSE patient, histological 
features of pyknotic and karyolytic pyramidal neurons (arrows). 
b, inset neuronal necrosis and parenchymal rarefaction in associa-
tion with astrocytes containing intranuclear eosinophilic inclusion 
bodies. c Early degenerative and inflammatory changes of the grey 
matter associated with two astrocytes containing intranuclear inclu-
sion bodies (arrows). d Discrete area of grey matter rarefaction with 
marked inflammatory cell infiltrate. e Control RTA patient showing 
unaltered neurons. f Inset hippocampus, dentate gyrus, immunoper-
oxidase HSV-1 antigen stain [brown (DAB)] is largely restricted to 
nuclei. Inset image astrocyte with enlarged dense HSV-1 staining of 
the nucleus. Scale bars 50 μm (a, b, d–f), 20 µm (c)
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(CO1, CO2, CO3) and twelve nuclear encoded (COX4I1-
COX8C) subunits, there was a lower abundance for mito-
chondrial compared to nuclear encoded transcripts in HSE 
cases (Fig. 3a).
In the set of transcripts exhibiting significantly lower 
abundance in HSE tissue, transcripts encoding for other 
cellular components were also significantly over-repre-
sented (smaller numbers of transcripts with weaker sig-
nificance compared to mitochondrial components). These 
included the small ribosomal subunit, microtubule associ-
ated complex, kinesin complex, neuronal/dendritic spine 
and laminin (Table S5, Online Resource 1). No host tran-
scripts exhibited significantly higher abundance in HSE 
compared to control tissue. Transcripts encoding for apop-
totic mediators did not display any consistent changes in 
abundance in HSE tissue (Fig. 3b).
Consecutive tissue sections across the different brain 
regions for HSE cases and controls were immunostained 
for CO1 and HSV-1. An inverse pattern of staining for CO1 
and HSV-1 was observed within the HSE tissue (Figs. 4, 
5a, b). The percentage of the tissue area stained for CO1 
and HSV-1 was quantified in cingulate and insula regions 
(these regions exhibited limited necrosis) via Image J 
analysis software. There was an inverse correlation (Spear-
man rank correlation coefficient) between the percentage 
areas stained for HSV-1 and CO1 in all three patients; sig-
nificant in two, the third patient showing the same trend 
(r = −0.66, p = 0.044; r = −0.9, p = 0.005; r = −0.8, not 
significant, respectively; Fig. 5c).
Interpretable results for dual IF and double IP staining 
were obtained from isolated cingulate sections in a single 
HSE patient. The remaining sections exhibited poor reactiv-
ity. An insufficient number of images could be obtained to 
undertake a systematic assessment of HSV and mitochon-
drial (CO1 or TOMM70) staining. Accepting this limita-
tion, qualitatively, the IF staining captured a single HSV-1 
infected cell which exhibited nuclear (DAPI) but not mito-
chondrial (TOMM70) stain. In contrast, cells in the nearby 
tissue stained for TOMM70. Similarly, IP staining of the cin-
gulate tissue demonstrated widespread nuclear staining for 
HSV-1, with occasional dense cytoplasmic staining for CO1; 
Supplementary Figures S1 and S2 (Online resource 2).
Transcript abundance for CO1 and COX6A1 (mitochon-
drial and nuclear DNA encoded enzyme subunits for CO) 
were re-measured in brain tissue using qPCR (Fig. 5d). 
Two experimental replicates from each brain region (cin-
gulate, amygdala, and frontal) were examined among 
HSE cases (n = 3) and controls (n = 5). Both CO1 and 
COX6A1 exhibited lower abundance in cases compared to 
controls across the brain regions. The reduction was only 
significant for CO1 [p = 0.032 (two-way repeated meas-
ures ANOVA)], with a greater reduction in abundance for 
CO1 than COX6A1 [mean CT difference 3.63 ± 95 % con-
fidence intervals (CI) 1.48–5.77 versus 1.57 ± −2.65–5.78 
for CO1 and COX6A1, respectively].
Next, we used cultures of primary human astrocytes to 
investigate the HSV-1 related mitochondria damage over 
time. Purity of the astrocyte cultures was confirmed via 
GFAP labelling. Active HSV-1 infection was confirmed 
by a high proportion of astrocytes exhibiting intranuclear 
inclusions [Figs. S3 and S4 (Online resource 3)]. During 
in vitro infection, HSV-1 DNA abundance increased, reach-
ing a maximum at 48 h pi (Fig. 6a). There was a reduc-
tion in both mitochondrial (CO1) and nuclear (DAD1) 
transcripts during HSV-1 infection relative to non-infected 
cells. At 36 h pi, CO1 transcript abundance was lower 
among infected compared to non-infected cells. This early 
reduction was not observed for DAD1 (Fig. 6b). CO1 cor-
rected for DAD1 abundance was significantly lower at 
this time-point (p = 0.036). TNF transcript abundance 
increased during infection relative to non-infected cells 
Fig. 2  Heat-map of relative transcript abundance in the brain of HSE 
cases and controls. Samples are manually organised on the x axis; A–
C represent HSE patients, 1–5 represent control patients. Transcripts 
are hierarchically clustered by similarity of transcript abundance on 
the y axis (n = 2882). Transcripts with high abundance (relative to 
median value for the set) are exhibited as magenta tiles; those with 
low abundance—green; and those at median—black. Although there 
was variation in transcript abundance between the HSE cases, with 
cases B and C exhibiting a greater proportion of down-regulated tran-
scripts compared to case A, there remained a cluster of 287 transcripts 
[green tiles in the top left of the heat-map (asterisk)] that exhibited 
significantly (FDR <5 %) lower abundance in HSE cases (n = 3) 
compared to controls (n = 5). This set of transcripts was significantly 
(p < 0.0001) over-represented with transcripts corresponding to mito-
chondrial DNA encoded genes. Gene-expression was visualised as a 
heat-map using Treeview 1.60 (http://www.eisenlab.org)
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(Fig. 6c). The apoptotic mediators, BCL2, BAX, BAK, 
CASP3, CASP8, CASP9, PUMA, NOXA, and MCL-1 
did not show any significant changes in transcript abun-
dance during infection [Fig. 6c, Fig. S5 (Online resource 
4)]. Non-infected astrocytes did not exhibit any significant 
changes in transcript abundance.
Among astrocytes recovered from the infection time-
course, there was progressive reduction in the proportion 
of DAPI positive cells expressing CO1, while the propor-
tion expressing HSV-1 increased, over time pi. Non-infected 
cells exhibited stable CO1 expression, with no HSV-1 
detected (Fig. 7).
Sequential histochemical testing for CO and then SDH 
activity in infected astrocytes was used to demonstrate an 
early loss of CO function. Like many mitochondrial enzymes, 
CO is composed of subunits encoded by both mitochondrial 
and nuclear genome. In contrast, SDH is the only enzyme in 
the respiratory chain composed of subunits encoded entirely 
by the nuclear genome. Sequential histochemistry is used as a 
functional screen for mitochondrial genome related defects in 
clinical settings [11]. If enzymes derived from the mitochon-
drial genome are selectively impaired during HSV-1 infec-
tion, a loss of CO function but maintenance of SDH function 
would be expected (Figs. 8, 9).
At 6 h pi, the majority of the monolayer stained with 
DAB, indicating intact CO function (Figs. 8a, 9a). At 24 h 
pi, multiple ‘blue patches’ were observed in the monolayer. 
These ‘blue patches’ represented cells with impaired CO 
function (failure to oxidise DAB), but maintenance of SDH 
function [sustained ability to reduce NBT (Figs. 8b, 9b)]. 
Fig. 3  Relative abundance for mitochondrial and apoptotic tran-
scripts in HSE. Y axis represents mean log (base 2) fold change in 
abundance for individual transcripts among HSE cases relative to 
controls. Replicate transcripts have been collapsed to their arithme-
tic mean. Negative values represent lower abundance in HSE tissue. 
a Mitochondrial DNA encoded transcripts exhibit lower abundance 
compared to nuclear DNA encoded mitochondrial transcripts (right 
compared to left side of X axis). Among transcripts corresponding to 
the cytochrome c oxidase enzyme complex, mitochondrial encoded 
transcripts (red hatched bars) exhibit lower abundance than nuclear 
encoded transcripts (red solid bars). For succinate dehydrogenase, 
nuclear encoded transcripts (green solid bars) exhibit relatively high 
abundance compared to mitochondrial encoded transcripts. b Tran-
scripts encoding for apoptotic mediators did not show any consistent 
or significant changes in abundance in HSE tissue compared to con-
trols
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Later, further blue patches of cells and loss of cells from 
the monolayer were observed, with a progressive decrease 
in the area of DAB staining (Figs. 8c, d, 9c, d). Among 
non-infected astrocytes the majority of the monolayer 
stained with DAB throughout the time-course (Fig. 8e–h). 
Independent review of masked images gave consist-
ent results; ranked non-infected, 6, 24, 48 and 72 h pi for 
decreasing area of DAB staining.
There was a progressive reduction in viable astrocyte 
cell number (unstained for trypan blue) among infected 
Fig. 4  Pattern of distribution of CO1 and HSV-1 antigen expression 
in brain tissue from HSE patients. Consecutive brain tissue sections 
were immunoperoxidase stained for either CO1 or HSV-1 antigen. 
All regions show an inverse pattern of staining for CO1 and HSV-1. 
a Hippocampus, CA2 region, diffuse granular CO1 staining in the 
neuropil, with a relative lack of CO1 staining in the dentate gyrus. b 
Hippocampus, CA2 region (consecutive section); absence of HSV-1 
staining in the neuropil, with strong HSV-1 staining restricted to the 
dentate gyrus. c Frontal cortex, moderate granular CO1 staining in 
neurons. d Frontal cortex (consecutive section); strong HSV-1 antigen 
staining in neurons. e Amygdala, strong CO1 reaction among large 
neurons. f Amygdala (consecutive section); limited HSV-1 antigen 
staining among large neurons. Scale bars 250 μm (a, b), 100 μm 
(c–f). Note; although strong HSV-1 antigen staining was observed in 
neurons, no intranuclear inclusions were observed in these cells
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cultures over the time-course. Cell number in non-infected 
cultures remained stable. At 48 and 72 h pi, infected astro-
cytes changed from a stellate to a globoid morphology with 
loss of their astrocytic processes [Table S6 and Fig. S6 
(Online resource 4)].
Transmission electron microscopy of cultured astro-
cytes demonstrated consistent ultra-structural changes 
within infected cells. These changes were classified as 
‘early’, ‘intermediate’ and ‘late’. At 24 h pi, the majority 
of cells exhibited ‘early’ changes. At 72 h pi, the major-
ity of cells exhibited ‘late’ changes. The ultra-structural 
changes were in agreement with previous reports [7, 36]. In 
the ‘early’ phase, mitochondria were clustered in the cen-
tral cytoplasm. They appeared condensed with increased 
electron density of their cristae. No structural disarrange-
ments of nuclear chromatin or membrane were observed 
(Fig. 10b). During the ‘intermediate’ phase, mitochondria 
were enlarged, with intra-cristal swelling and whirling of 
their membranes. Cells were swollen, with loss of chroma-
tin granularity (Fig. 10c). In the ‘late’ phase, mitochondria 
were severely swollen and degraded. There was dramatic 
swelling of the cell and nucleus, loss of chromatin granu-
larity, and membrane disintegration (Fig. 10d). Mature 
enveloped virions decorated the extracellular aspect of the 
Fig. 5  Quantification of CO1 and HSV-1 antigen expression in brain 
tissue from HSE patients. Consecutive brain tissue sections were 
immunoperoxidase stained for either CO1 or HSV-1 antigen. a Cin-
gulate gyrus, moderate CO1 expression. b Cingulate gyrus, neurons 
with strong HSV-1 reaction. Scale bars 100 μm. c Quantification of 
immunostaining in consecutive sections of the cingulate cortex for 
two HSE cases (A, C); cingulate and insula for the third HSE case 
(B). The proportion (%) of the area of tissue staining positively for 
either CO1 or HSV-1antigen was measured in sets of ‘paired’ images 
of the same field of view [n = 4 images for case 1 (squares) and 
n = 5 for case 2 (circles)]. There is a significant negative correlation 
between HSV-1and CO1 antigen staining for two cases (A, C) with 
the third case (B) showing the same negative trend (Spearman rank 
correlation coefficient; r = −0.66, p = 0.044; r = −0.9, p = 0.005; 
r = −0.8, not significant; respectively, for HSE patients A, C, B). d 
Measurement of CO1 transcript abundance in tissue from amygdala, 
frontal and cingulate regions among HSE cases and controls. Abun-
dance for CO1 is significantly lower in cases compared to controls 
(p = 0.032); 2-way repeated measures ANOVA over 3 brain regions 
(two tissue sections per region) for cases (black circles) against con-
trols (grey squares). CO1 abundance measured as 1/CT (PCR frac-
tional cycle number for threshold fluorescence). Mean and 95 % CI 
presented [cases (n = 3) and controls (n = 5)]
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plasma membrane at all time-points pi (Fig. 10b, inset). 
Non-infected astrocytes did not exhibit cellular degradation 
or HSV-1 particles (Fig. 10a). There was a steady decline 
in the number of normally conformed mitochondria within 
cells with time pi [mean 35.8 (±95 % CI 23.2–48.4); 17.6 
(8.1–27.1); 13.4 (2.9–23.8); 3.2 (−1.9 to 8.3); for non-
infected, 24, 48 and 72 h pi, respectively].
There was significantly higher CO1 transcript abundance 
in minocycline treated compared to non-treated infected 
astrocyte cultures [p = 0.029 (normalised for changes in 
DAD1); Fig. 11a]. Sequential histochemical testing demon-
strated maintenance of CO activity at 24 and 48 h pi among 
minocycline treated infected cells (Fig. 12a, b). In contrast, 
prominent blue patches, indicating loss of CO but mainte-
nance of SDH activity, were seen at 24 and 48 h pi among 
non-treated cells (Fig. 12c, d). At 48 h pi, there was also 
a significantly greater loss of the cell monolayer (reduced 
area stained for CO or SDH activity) among non-treated 
compared to treated cells [p = 0.046; area (proportion) of 
staining is documented in Table S7 (Online resource 5)].
Transcript abundances for BCL2 and BAX were sig-
nificantly increased over 2–24 h pi in minocycline treated 
compared to non-treated infected astrocytes (p = 0.004, 
p = 0.012); IL-6 was significantly decreased over all time-
points in treated cells (p < 0.0001). TNF also showed a 
trend for decreased abundance in treated cells (Fig. 11b–e).
There was no significant difference in HSV-1 DNA 
abundance in minocycline and aciclovir co-treated cul-
tures, compared to those treated with aciclovir alone dur-
ing infection (Fig. 11f). To confirm whether minocycline 
had anti-viral properties, we examined HSV-1 replication 
in the presence and absence of the drug in HeLa cells. The 
results indicated minocycline alone promoted viral replica-
tion. However, there was no significant difference in HSV-1 
replication in aciclovir and minocycline co-treated cells 
compared to aciclovir alone (Online resource 5). Exposing 
uninfected astrocytes to minocycline, there was no change 
in cell number, morphology or viability compared to non-
exposed cells over 72 h (Figs. S6, S9 and S10; Online 
resource 4 and 5).
Discussion
This is the first investigation of the human host transcrip-
tome in HSE brains and the first study of the effect of 
minocycline on HSV-1 infection.
Host transcriptome analysis demonstrated a profound 
reduction in mitochondrial related transcript abundance 
in post-mortem HSE brain tissue. Transcripts encoded by 
MtDNA were significantly over-represented among low 
abundant host transcripts. Reductions in mitochondrial 
Fig. 6  HSV-1 and host transcript abundance during in vitro HSV-1 
infection. Viral DNA and host RNA from the infected human astro-
cytes were examined at indicated time-points via qPCR and qRT-
PCR, respectively. a Increase in HSV-1 DNA (solid circles) abun-
dance (CT) during the course of infection, reaching a maximum at 
48 h pi. b Decrease in transcript abundance (CT) for CO1 (circles) 
and DAD1 (squares) among infected (solid symbols) relative to 
non-infected cells (open symbols), reaching a nadir at 72 h pi. Early 
decrease in CO1 (solid circles) over the first 36 h, with relative abun-
dance [δCT (CO1-DAD1)] significantly lower at 36 h pi (p = 0.036). 
At the same time-point, no change in DAD1 abundance between 
infected and non-infected cells. c TNF (circles) exhibits a signifi-
cant increase in relative abundance [δCT (TNF-DAD1)] at 72 h pi 
(p = 0.029) among infected (solid circles) relative to non-infected 
astrocytes (open circles). CASP3 (squares) exhibits no significant 
change in relative transcript abundance [δCT (CASP3-DAD1)] during 
infection. Data presented as mean ± 95 % confidence interval (CI) 
for each experimental group (minimum of 3 replicate experiments per 
group). Differences in CT at 36 and 72 h pi assessed using the Mann–
Whitney U test
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transcript abundance were not observed in control tissue, 
indicating the changes were not secondary to agonal or 
post-mortem processes. Our human brain tissue findings 
support previous studies in non-neuronal cell lines, demon-
strating a preferential and marked decline in mitochondrial 
transcripts and MtDNA following HSV infection [33, 45]. 
While some degree of MtDNA damage has been linked to 
many degenerative and/or pathological processes, profound 
MtDNA depletion is less common. The latter process has 
been reported in association with HSV-1, HSV-2 and EBV 
virus infection. It has also been reported in genetic mito-
chondrial syndromes, profound oxidant exposure and zido-
vudine therapy [9, 18, 43, 49].
Beyond mitochondrial related transcripts, we observed 
a decline in transcripts encoding for the small ribosomal 
subunit, the microtubule associated complex; neuronal/
dendritic spine, kinesin complex and laminin. It is well 
reported, HSV interacts with small and large ribosomal 
subunits during active infection and subverts control of 
neuron axonal transport (including the kinesin complex), 
microtubule movement, and neuronal dendrite formation 
during infection [14, 16, 17, 30, 35]. Susceptibility of cells 
to HSV-1 infection is reported to vary depending on the 
extracellular matrix [48]. Reduced transcript abundance for 
laminin, a component of extracellular matrices, may again 
be linked with HSV-1 infection. We also observed a gen-
eral reduction in host nuclear transcript abundance in HSE 
tissue compared to controls. Again, this supports previous 
in vitro studies reporting viral host shut-off of transcription 
and a decrease of cellular RNA abundance following HSV 
infection [31, 33, 34].
Supporting the decrease in mitochondrial transcripts, 
there was a corresponding reduction in CO1 protein in HSE 
tissue. CO1 staining was reduced in neurons and supporting 
Fig. 7  CO1 and HSV-1 antigen expression during in vitro HSV-1 
infection. Dual immunofluorescence: infected human astrocytes 
were labelled CO1 (green) and HSV-1 (red) antigens with DAPI 
nuclear counter-stain (blue). a At 6 h pi, a granular reaction for 
CO1 is detected in majority of cells, with HSV-1 antigen expression 
observed in occasional cells. b At 72 h pi, HSV-1 antigen is expressed 
in majority of cells, with no apparent CO1-positive cells. The nuclei 
appear slightly larger compared to early infected and non-infected 
cells. This may represent nuclei swelling following infection [see 
TEM images (Fig. 10)]. c Non-infected astrocytes are positive for 
CO1, with no HSV-1 expression at 72 h pi. Scale bars 100 μm. d 
Plot of proportion of astrocytes expressing HSV-1 and/or CO1 anti-
gen among non-infected (ni) and HSV-1 infected cultures at 6, 24, 48 
and 72 h pi. Y axis—proportion. X axis—hours pi. Grey bars CO1 
expressing cells. Hatched bars HSV-1 expressing cells. There is pro-
gressive reduction in CO1 and steady rise in HSV-1 antigen expres-
sion over time pi. Proportions are corrected for number of positive 
DAPI (nuclear) staining cells
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cells, including astrocytes. Furthermore, there was an 
inverse correlation between CO1 and HSV-1 expression 
within the HSE cases. Tissue regions with high HSV-1 
expression exhibited low CO1 expression and vice versa. 
Our brain tissue findings, support previous studies in non-
neuronal cell lines demonstrating a reduction in CO protein 
following HSV infection [40]. In addition, the inverse cor-
relation between CO1 and HSV-1 expression supports pre-
vious in vitro studies in non-neuronal cell lines indicating 
mitochondrial damage is mediated by active HSV-1 infec-
tion [45]. Astrocytes are increasingly recognized to have a 
pivotal role in protecting and supporting neuronal function 
[2]. Consequently, mitochondrial damage, both directly 
within neurons, and indirectly within astrocytes, has poten-
tial to contribute to neuronal injury during HSE.
We undertook in vitro studies to explore the tempo-
ral relationship between HSV infection and the mito-
chondrial changes observed in HSE tissue. There was a 
steady decline in CO1 transcript and protein abundance 
as HSV-1 infection progressed. We observed a progres-
sive reduction in both CO1 (MtDNA encoded) and DAD1 
(nuclear encoded) transcripts. However, there was an ear-
lier reduction in transcript abundance in CO1 compared 
to DAD1. Similarly, we observed a progressive reduction 
Fig. 8  Mitochondrial enzyme function during in vitro HSV-1 infec-
tion. a–d Sequential enzyme histochemistry of cytochrome c oxidase 
CO (brown) and succinate dehydrogenase SDH (blue) mitochon-
drial enzyme activity demonstrate an early loss of CO function dur-
ing infection. a At 6 h pi, uniform brown stain indicates that CO is 
functional. b At 24 h pi, early impairment of CO activity, with sus-
tained SDH activity, is evidenced by patches of blue, CO-negative, 
SDH-positive cells. c, d At 48 and 72 h pi, both CO dysfunction and 
cell death is evidenced by further blue patches and loss of continuity 
of the cell monolayer. e–h In non-infected astrocytes, CO remained 
active throughout the time-course [6 h (e), 24 h (f), 48 h (g) and 72 h 
pi (h)]. Scale bars 200 μm (a–d), 300 μm (e–h)
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in CO1 antigen staining, with an increase in HSV-1 stain-
ing, among DAPI positive astrocytes during infection. 
Infected astrocytes exhibiting impaired CO enzyme activ-
ity at 24 h pi were still firmly attached to the flask sur-
face and retained their stellate morphology. Similarly, cell 
ultra-structural changes such as central migration of mito-
chondria and cristae condensation were observed prior 
to changes in the nucleus. Saffran and colleagues previ-
ously demonstrated a rapid and preferential loss of mito-
chondrial transcripts following HSV-1 in vitro infection 
of non-neuronal cells [45]. Migration of HSV-1 proteins 
into mitochondria has been reported to trigger degradation 
of MtDNA, i.e. via pUL12.5, or suppress mitochondrial 
enzyme activity, i.e. via US3 [10, 13, 45]. Our in vitro 
Fig. 9  Quantification of cytochrome c oxidase enzyme function dur-
ing in vitro HSV-1 infection. The proportion of cells adherent to the 
flask surface (within the monolayer) and exhibiting intact cytochrome 
c oxidase (CO) function was quantified. a–d The area (%) of the 
monolayer staining positively for DAB (false red) was measured at 
6, 24, 48 and 72 h pi. e Area of DAB staining declined from 87.52 
to 50.54, 25.53 and 19.04 % over time pi. f Area of DAB staining 
remained above 80 % throughout time-course among non-infected 
cells, data are presented as mean ± 95 % CI for each time-point. 
Replicate cultures were examined per time-point (n = 3)
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Fig. 10  Ultra-structural cellular changes following in vitro HSV-1 
infection. a In non-infected cells, mitochondria are scattered through-
out the cytoplasm (arrows) with a centrally located nucleus exhibit-
ing granular chromatin. b ‘Early’ morphological changes: HSV-1 
infected cell exhibit central clustering in the cytoplasm (arrow) of 
‘condensed’ mitochondria (top inset). Viral particles are detected in 
the nucleus, cytoplasm and budding on the surface of the cell (bot-
tom inset). c ‘Intermediate’ morphological changes: mitochondria 
are swollen (arrow/inset) with intra-cristal enlargement and whirling 
of the mitochondrial membrane (inset). The nucleus exhibits loss of 
chromatin granularity. d ‘Late’ morphological changes: mitochondria 
are markedly enlarged (inset); the cell is dramatically swollen, the 
nucleus exhibits a severe loss of chromatin granularity and its mem-
brane appears fragmented. Scale bars 2 μm
Fig. 11  Comparison of host transcript and HSV-1 DNA abundance in minocycline treated and non-treated astrocytes during in vitro HSV-1 
infection. Viral DNA and host RNA from infected human astrocytes were examined at indicated time-points via qPCR and qRT-PCR, respec-
tively. Relative transcript abundance. a CO1 (circles) and DAD1 (squares), b BCL2, c BAX, d IL-6, e TNF in HSV-1 infected non-treated 
(solid symbols) compared to HSV-1 infected minocycline treated (open symbols) astrocyte cultures; f HSV-1 DNA in non-treated (solid circles) 
compared to minocycline (60 µM) treated (open circles); minocycline + aciclovir (20 µM) co-treatment (open squares) and aciclovir (20 µM) 
alone (solid squares) among HSV-1 infected astrocytes. Y axis—relative transcript abundance δCT (difference in CT in infected minus non-
infected; a or δδCT (difference for target gene—DAD1 in infected minus non-infected cultures; b–f X axis—hours pi. Data are presented as 
mean ± 95 % CI for each experimental group (minimum of 4 experiments per group). a CO1 exhibits sustained abundance during infection 
in minocycline treated compared to non-drug exposed cells. There is a significant difference in relative transcript abundance [δδCT (CO1-
DAD1)] between exposures (p = 0.029) at 48 h pi. DAD1 exhibits a smaller decrease in transcript abundance (δCT) in minocycline compared 
to non-drug exposed cells (not-significant). b BCL2 and c BAX exhibit significant increases in relative transcript abundance among minocy-
cline exposed compared to non-drug exposed cultures between 2 and 24 h pi (p = 0.004, p = 0.012, respectively). d IL-6 exhibits significant 
decrease in transcript abundance among minocycline treated compared to non-drug exposed astrocyte cultures between 4–72 h pi (p < 0.0001). 
e TNF exhibits similar trend to IL-6. f HSV-1 DNA shows no significant change in relative transcript abundance [δδCT (HSV-1 minus DAD1) 
in infected minus non-infected cultures] in either minocycline treated compared to non-treated or minocycline and acyclovir co-treated com-
pared to aciclovir alone. Significant differences in δδCT were assessed using 2-way repeated measures ANOVA (column factor—drug expo-
sure; row factor—time pi) using time-points: 2, 4, 6, 24 h (b, c) and 4, 6,24, 32, 48, 72 h (e). The Mann–Whitney U test was used to compare 
corrected CO1 abundance at 48 h pi (a)
◂
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findings, together with these reports, support the notion 
that mitochondrial dysfunction is an early process during 
HSV-1 infection, which occurs before nuclear and cellular 
functions are significantly impaired.
This is the first study to demonstrate an early loss of 
mitochondrial function among respiratory chain enzymes 
encoded by MtDNA following HSV-1 infection. CO is the 
last enzyme in the electron transport chain (complex IV). 
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CO is composed of enzyme subunits encoded via both 
MtDNA (i.e. CO1, CO2 and CO3) and nuclear DNA (e.g. 
COX6A1). In contrast, SDH is a respiratory chain enzyme 
(complex II) whose subunits (i.e. SDH A, B, C and D) are 
entirely encoded by nuclear DNA [11]. Infected astrocytes 
demonstrated impaired CO function at 24 h pi. In contrast, 
SDH function was maintained at 24 h. This early loss of 
CO function, but maintenance of SDH function, could be 
explained by loss of MtDNA encoded transcripts. CO1, 
CO2 and CO3 all exhibited low transcript abundance, 
whereas SDH A-D showed relatively higher abundance in 
HSE tissue. HSV-1 protein, pUL12.5, is reported to migrate 
into mitochondria during infection, and trigger a rapid deg-
radation of MtDNA within 48 h pi, via the viral product’s 
exonuclease activity [10]. Indirect mechanisms could also 
trigger MtDNA depletion during HSV-1 infection, such as 
increased oxidant stress or viral induced alterations (tran-
scriptional and/or post-transcriptional) in host mitochon-
drial repair, programmed cell death or transcriptional path-
ways [34, 44, 49].
HSE has classically been described as a necrotizing 
process [5, 21]. More recently, apoptosis has also been 
observed to contribute to death of neurons and glia in HSE 
brain tissue [4, 12]. Some in vitro and in vivo models of 
HSE have reported brain cell death via apoptosis [3, 23], 
whereas other studies have reported an absence of apoptosis 
following in vivo HSV-1 brain infection [20]. During our 
in vitro studies, we observed changes in cell ultra-structure 
classically associated with necrosis, such as mitochondrial 
swelling, nuclear swelling, cell swelling and membrane 
disintegration [56]. There was no consistent up-regulation 
of transcript abundances for apoptotic mediators among 
in vitro infected astrocytes or HSE brain tissue. Again, 
these results suggest apoptosis is not the main mecha-
nism of cell loss during HSE. While we accept consistent 
changes in host apoptotic pathways may be obscured by 
variable rates of cell death occurring among different cells 
in the brain tissue, we did observe a consistent reduction in 
mitochondrial related transcripts in HSE tissue, weakening 
the latter argument.
Minocycline is reported to limit brain cell damage in 
models of viral encephalitis, including West Nile virus, 
Japanese Encephalitis Virus, Reovirus and HIV. How-
ever, it exacerbated brain damage in models of Rabies 
virus [26, 38, 39, 42, 55]. To date, minocycline has not 
been studied in HSE. Minocycline is reported to sus-
tain mitochondrial and brain cell function by several 
mechanisms, including inhibition of apoptosis, via induc-
tion of the mitochondrial anti-apoptotic mediator BCL-
2, suppression of mitochondrial pro-apoptotic mediators 
(e.g. BAX), maintenance of mitochondrial membrane 
integrity, reduced leakage of cytochrome c into the cyto-
plasm and suppression of pro-inflammatory mediators 
[27, 53]. Our results indicate minocycline protects mito-
chondrial function and cell viability during HSV-1 infec-
tion, with reduced loss of CO1 transcripts, sustained CO 
activity and better maintenance of the cell monolayer. As 
previously reported, our findings suggest minocycline 
protects cells through multiple mechanisms [8, 51]. The 
pro-inflammatory mediators IL-6 and TNF exhibited 
decreased abundance, whereas the mitochondrial anti- 
and pro-apototic mediators, BCL-2 and BAX, exhibited 
increased abundance.
Minocyline is reported to reduce viral replication in 
HIV, West Nile, and JE viruses [38, 39, 55]. In astrocytes, 
minocycline did not impact on HSV-1 DNA abundance. 
In Hela cells, minocycline, alone, promoted HSV-1 repli-
cation. However, there was no change in virus replication 
with minocycline and aciclovir co-treatment. Further stud-
ies are required to explore minocycline’s mechanisms of 
action. Validation of minocycline’s mitochondrial protec-
tion will benefit from further work in human neurons and/
or animal models of HSE.
The in vitro culture of primary human astrocytes may 
not reflect the complexity of HSV-1 infection during 
encephalitis. However, both human brain tissue and human 
astrocyte cultures exhibited astrocytic inclusion bodies 
(pathognomonic feature of human HSV-1 infection [21]). 
Both exhibited a selective loss of mitochondrial transcripts 
and/or mitochondrial protein that was linked to increasing 
abundance of HSV-1. Neither brain tissue nor astrocyte 
culture exhibited any consistent changes in abundance for 
apoptotic mediators following HSV-1 infection. Conse-
quently, astrocyte cultures reflected key changes in human 
brain tissue from HSE cases.
In conclusion, HSE patients demonstrate a preferen-
tial loss of mitochondrial transcripts and a corresponding 
loss of mitochondrial protein in post-mortem brain tissue. 
In vitro studies showed early transcript reduction, early 
mitochondrial enzyme dysfunction and early mitochon-
drial ultra-structural damage, prior to nuclear and cell 
damage, following HSV-1 infection. Minocycline sus-
tains mitochondrial transcript abundance, mitochondrial 
enzyme function and astrocyte viability. The study provides 
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compelling data to stimulate further investigations of mino-
cycline and other agents focussing on mitochondrial pro-
tection as an adjunctive treatment for HSE.
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Fig. 12  Comparison of cytochrome c oxidase function in minocy-
cline treated and non-treated astrocytes during in vitro HSV-1 infec-
tion. Sequential enzyme histochemistry of cytochrome c oxidase CO 
(brown) and succinate dehydrogenase SDH (blue) activity demon-
strates protective properties of minocycline. a, b At 24 and 48 h pi, 
vast majority of cells stain brown indicating intact CO function in 
minocycline treated cells. c, d At 24 and 48 h pi, obvious patches of 
cells stain blue, indicating impaired CO, but sustained SDH activity 
among non-treated cells. There is also a greater loss of the cell mon-
olayer (reduced area stained for CO or SDH activity) among non-
treated cells Area (proportions) for monolayer staining is documented 
in Table S7 (Online resource 5). Scale bars 200 μm
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link to the Creative Commons license, and indicate if changes were 
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